<p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）在週五發佈的報告中，摩根大通將其目標價格從 30.00 美元下調至 28.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “增持”。</p>
<p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾家券商也對 OLMA 發佈了報告。HC Wainwright 在 3 月 19 日的研究報告中重申了對 Olema Pharmaceuticals 的 “買入” 評級，並設定了 30.00 美元的目標價格。Oppenheimer 在 3 月 19 日的報告中重申了 “跑贏大盤” 的評級，並將 Olema Pharmaceuticals 的目標價格設定為 25.00 美元（之前為 30.00 美元）。</p>
<p><strong>查看我們最新的 Olema Pharmaceuticals 股票報告</strong></p>
<h2>Olema Pharmaceuticals 價格表現</h2>
<p>週五，OLMA 股票開盤價為 4.20 美元。該股票的市值為 2.87 億美元，市盈率為-1.92，貝塔係數為 2.11。該公司的 50 日簡單移動平均線為 5.02 美元，200 日簡單移動平均線為 8.14 美元。Olema Pharmaceuticals 的年內最低價為 3.93 美元，最高價為 16.62 美元。</p>
<p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）最近在 3 月 18 日發佈了季度財報。該公司報告季度每股收益為（0.51 美元），超出分析師一致預期的（0.63 美元）0.12 美元。整體來看，研究分析師預計 Olema Pharmaceuticals 在當前年度的每股收益將為-2.33 美元。</p>
<h2>Olema Pharmaceuticals 內部活動</h2>
<p>在相關消息中，主要股東 Bain Capital Life Sciences Inv 於 1 月 8 日購買了 30 萬股該公司的股票。該股票的平均購買價格為每股 5.76 美元，總交易額為 1,728,000.00 美元。購買後，該內部人士現在直接持有 780 萬股公司股票，估值約為 44,928,000 美元。此交易代表其持股比例增加了 4.00%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。19.40% 的股票由內部人士持有。</p>
<h2>對 Olema Pharmaceuticals 的對沖基金看法</h2>
<p>機構投資者和對沖基金最近買賣了該公司的股票。Intech Investment Management LLC 在第三季度購買了 Olema Pharmaceuticals 的新頭寸，價值為 163,000 美元。Charles Schwab Investment Management Inc.在第三季度將其在 Olema Pharmaceuticals 的持股比例提高了 168.5%。Charles Schwab Investment Management Inc.現在持有該公司 330,761 股股票，價值為 3,949,000 美元，此前在該期間內又增持了 207,565 股。Dynamic Technology Lab Private Ltd 在第三季度購買了 Olema Pharmaceuticals 的新股份，價值約為 238,000 美元。Portland Investment Counsel Inc.在第三季度購買了 Olema Pharmaceuticals 的新股份，價值約為 143,000 美元。最後，Ikarian Capital LLC 在第三季度購買了 Olema Pharmaceuticals 的新頭寸，價值約為 1,098,000 美元。91.78% 的股票由機構投資者持有。</p>
<h2>Olema Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Olema Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於女性癌症治療的發現、開發和商業化。其主要產品候選藥物為 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；同時 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行一期/二期臨牀試驗，治療複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌，並開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Olema Pharmaceuticals</li>
<li>2025 年可能大幅上漲的兩隻 CRM 平台股票</li>
<li>Ibotta 股票：為何回購看起來像是一個看漲的賭注</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>Joby Aviation 股票：分析師信心與聰明資金一致</li>
<li>如何投資小型股</li>
<li>3 只接近 52 周高點的動量股，值得關注以獲取更多增長</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
<p>在考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Olema Pharmaceuticals 並不在名單上。</p>
<p>雖然 Olema Pharmaceuticals 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

摩根大通

OLMA

<p>摩根大通已將 Olema Pharmaceuticals（納斯達克代碼：OLMA）的目標股價從 30.00 美元下調至 28.00 美元，同時維持 “增持” 評級。其他券商也給出了不同的評級，HC Wainwright 設定了 30.00 美元的目標，而 Oppenheimer 則將其下調至 25.00 美元。Olema 的股票開盤價為 4.20 美元，市值為 2.87 億美元。該公司報告的季度每股收益為（0.51 美元），超出預期。內部交易方面，貝恩資本生命科學購買了 300,000 股，增持了 4% 的股份</p>

<p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) had its price objective reduced by JPMorgan Chase &amp; Co. from $30.00 to $28.00 in a report released on Friday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）在週五發佈的報告中，摩根大通將其目標價格從 30.00 美元下調至 28.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “增持”。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other brokerages have also issued reports on OLMA. HC Wainwright reissued a &#34;buy&#34; rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. Oppenheimer restated an &#34;outperform&#34; rating and set a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.</p>
<div class="lb-trans"><p>其他幾家券商也對 OLMA 發佈了報告。HC Wainwright 在 3 月 19 日的研究報告中重申了對 Olema Pharmaceuticals 的 “買入” 評級，並設定了 30.00 美元的目標價格。Oppenheimer 在 3 月 19 日的報告中重申了 “跑贏大盤” 的評級，並將 Olema Pharmaceuticals 的目標價格設定為 25.00 美元（之前為 30.00 美元）。</p>
</div><p><strong>View Our Latest Stock Report on Olema Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Olema Pharmaceuticals 股票報告</strong></p>
</div><h2>Olema Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 價格表現</h2>
</div><p>Shares of OLMA stock opened at $4.20 on Friday. The stock has a market capitalization of $287.00 million, a PE ratio of -1.92 and a beta of 2.11. The business's 50 day simple moving average is $5.02 and its 200 day simple moving average is $8.14. Olema Pharmaceuticals has a one year low of $3.93 and a one year high of $16.62.</p>
<div class="lb-trans"><p>週五，OLMA 股票開盤價為 4.20 美元。該股票的市值為 2.87 億美元，市盈率為-1.92，貝塔係數為 2.11。該公司的 50 日簡單移動平均線為 5.02 美元，200 日簡單移動平均線為 8.14 美元。Olema Pharmaceuticals 的年內最低價為 3.93 美元，最高價為 16.62 美元。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. As a group, research analysts expect that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）最近在 3 月 18 日發佈了季度財報。該公司報告季度每股收益為（0.51 美元），超出分析師一致預期的（0.63 美元）0.12 美元。整體來看，研究分析師預計 Olema Pharmaceuticals 在當前年度的每股收益將為-2.33 美元。</p>
</div><h2>Insider Activity at Olema Pharmaceuticals</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 內部活動</h2>
</div><p>In related news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the firm's stock in a transaction dated Wednesday, January 8th. The stock was bought at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the purchase, the insider now directly owns 7,800,000 shares in the company, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，主要股東 Bain Capital Life Sciences Inv 於 1 月 8 日購買了 30 萬股該公司的股票。該股票的平均購買價格為每股 5.76 美元，總交易額為 1,728,000.00 美元。購買後，該內部人士現在直接持有 780 萬股公司股票，估值約為 44,928,000 美元。此交易代表其持股比例增加了 4.00%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。19.40% 的股票由內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Olema Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Olema Pharmaceuticals 的對沖基金看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC purchased a new position in shares of Olema Pharmaceuticals during the 3rd quarter valued at $163,000. Charles Schwab Investment Management Inc. raised its stake in Olema Pharmaceuticals by 168.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company's stock valued at $3,949,000 after acquiring an additional 207,565 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Olema Pharmaceuticals in the 3rd quarter valued at about $238,000. Portland Investment Counsel Inc. purchased a new stake in Olema Pharmaceuticals during the third quarter valued at about $143,000. Finally, Ikarian Capital LLC bought a new position in Olema Pharmaceuticals during the third quarter worth about $1,098,000. 91.78% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近買賣了該公司的股票。Intech Investment Management LLC 在第三季度購買了 Olema Pharmaceuticals 的新頭寸，價值為 163,000 美元。Charles Schwab Investment Management Inc.在第三季度將其在 Olema Pharmaceuticals 的持股比例提高了 168.5%。Charles Schwab Investment Management Inc.現在持有該公司 330,761 股股票，價值為 3,949,000 美元，此前在該期間內又增持了 207,565 股。Dynamic Technology Lab Private Ltd 在第三季度購買了 Olema Pharmaceuticals 的新股份，價值約為 238,000 美元。Portland Investment Counsel Inc.在第三季度購買了 Olema Pharmaceuticals 的新股份，價值約為 143,000 美元。最後，Ikarian Capital LLC 在第三季度購買了 Olema Pharmaceuticals 的新頭寸，價值約為 1,098,000 美元。91.78% 的股票由機構投資者持有。</p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於女性癌症治療的發現、開發和商業化。其主要產品候選藥物為 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；同時 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行一期/二期臨牀試驗，治療複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌，並開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Ibotta Stock: Why the Buyback Looks Like a Bullish Bet</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Joby Aviation Stock: Analyst Confidence and Smart Money Align</li>
<li>How to Invest in Small Cap Stocks</li>
<li>3 Momentum Stocks Near 52-Week Highs to Watch for More Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Olema Pharmaceuticals</li>
<li>2025 年可能大幅上漲的兩隻 CRM 平台股票</li>
<li>Ibotta 股票：為何回購看起來像是一個看漲的賭注</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>Joby Aviation 股票：分析師信心與聰明資金一致</li>
<li>如何投資小型股</li>
<li>3 只接近 52 周高點的動量股，值得關注以獲取更多增長</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Olema Pharmaceuticals 並不在名單上。</p>
</div><p>While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Olema Pharmaceuticals 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

摩根大通將 Olema Pharmaceuticals（NASDAQ:OLMA）的目標價下調至 28.00 美元